NICE recommends first new X-linked hypophosphataemia therapy in over 30 years
October 10, 2018Research and Development, Sales and Marketing Crysvita, Kyowa Kirin International, NHS, NICE, X-linked hypophosphataemia, pharma
NICE has announced its evidence-based recommendation that Kyowa Kirin International’s Crysvita (burosumab) be made available on the NHS for the …
Sackler-owned Mundipharma acquires biosimilar firm Cinfa Biotech
October 10, 2018Research and Development Mundipharma, biosimilar, cinfa biotech, sackler
In a bid to strengthen their biosimilar portfolio, the Cambridge based pain management company Mundipharma has acquired biosimilar development firm …
Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2
October 10, 2018Research and Development Novartis, crizanlizumab, pharma, sickle cell disease
Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …
WHO voices concern over British immigration policies after researchers refused entry
October 10, 2018Research and Development WHO, academia, immigration, research, universities
The World Health Organization (WHO) has expressed concern over the UK’s immigration polices, after a number of academics were refused …
Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO
October 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbot, Amgen, Bayer, civica rx, generic drugs, hospitals
Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen …
Menlo Therapeutics’ cough drug fails to meet primary endpoint in phase II trial
October 9, 2018Manufacturing and Production Phase II, cough, menlo therapeutics, serlopitant
The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet …
Janssen’s Stelara shows promise across two dosages in ulcerative colitis
October 9, 2018Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …
NICE guidelines on antidepressant withdrawal symptoms are misleading, study shows
October 9, 2018Manufacturing and Production NICE, UK, addiction, antidepressants, research, study
Current NICE guidance concerning the severity of the effects of antidepressant withdrawal is misleading doctors according to research published in …
Celgene’s Otezla impresses at Phase 3 in scalp psoriasis
October 9, 2018Manufacturing and Production, Research and Development Celgene, pharma, psoriasis
Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine …
New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs
October 9, 2018Manufacturing and Production PhRMA, aha, generics, hospitals, non profit, non-profit, pharma
Seven organisations representing around 500 US hospitals have become the governing members of a newly established initiative aimed at reducing …
The economics of mental health
October 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, health economics and outcomes research, mental health, pharma
Louis Goss examines mental health from a health economics and outcomes research (HEOR) perspective and asks what might be done …
NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia
October 8, 2018Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma
NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …
NIHR whitepaper claims UK needs High Throughput Centres after Brexit
October 8, 2018Sales and Marketing NHS, NIHR, UK, clinical trials, phase III
The National Institute for Health Research (NIHR) has released a new whitepaper outlining the substantial benefits NHS High Throughput Centres …
Tech firm Tencent aims for 3-minute Alzheimer’s diagnosis with new partnership
October 8, 2018Research and Development, Sales and Marketing Alzheimer's, pharma, tencent
Chinese tech firm Tencent has partnered up with London-based healthcare technology firm Medopad in a big to accelerate the diagnosis …
US FDA approves HPV vaccine for men and women aged 27-45
October 8, 2018Sales and Marketing CDC, Cancer, FDA, HPV, approval, infectious diseases, vaccines
The US Food and Drug Administration have approved the use of HPV vaccine Gardasil 9 for both men and woman …
MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar
October 8, 2018Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis
American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …
GSK to cut almost 200 jobs at UK site
October 5, 2018Manufacturing and Production, Medical Communications GSK, UK, Ulverston, job cuts, pharma
GlaxoSmithKline has announced that it is to slash half of its workforce at its site in Ulverston, UK, as part …
Top Ten most popular articles on Pharmafile.com this week
October 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Jannsen, NHS, Novartis, Novo Nordisk, dementia, top 10
As September came to a close and October began the UK was hit hard in the headlines after American firm …
FDA expands indication of Roche’s Hemlibra in haemophilia
October 5, 2018Medical Communications, Sales and Marketing Hemlibra, Roche, haemophilia, pharma
The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the …
NHS England appoves Gilead’s CAR T therapy Yescarta
October 5, 2018Medical Communications Gilead, NHS, NICE, UK, Yescarta
Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
